Literature DB >> 31690489

Complete Pathological Response to Crizotinib in a Patient with ALK-rearranged Lung Adenocarcinoma.

Marissa S Mattar1, Jason Chang2, Ryma Benayed2, Darragh Halpenny3, Astin Powers4, David E Kleiner4, Alexander Drilon5, Mark G Kris6.   

Abstract

Entities:  

Keywords:  EML4-ALK; EML4-ALK variants; Non–small-cell lung cancer; Tandem atypical propeller EML domain; Tyrosine kinase inhibitor

Mesh：

Substances：

Year:  2019        PMID： 31690489      PMCID： PMC6996866          DOI： 10.1016/j.cllc.2019.10.002

Source DB:  PubMed          Journal:  Clin Lung Cancer        ISSN： 1525-7304            Impact factor:   4.785


× No keyword cloud information.
  24 in total

1.  Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer.

Authors:  Justin F Gainor; Leila Dardaei; Satoshi Yoda; Luc Friboulet; Ignaty Leshchiner; Ryohei Katayama; Ibiayi Dagogo-Jack; Shirish Gadgeel; Katherine Schultz; Manrose Singh; Emily Chin; Melissa Parks; Dana Lee; Richard H DiCecca; Elizabeth Lockerman; Tiffany Huynh; Jennifer Logan; Lauren L Ritterhouse; Long P Le; Ashok Muniappan; Subba Digumarthy; Colleen Channick; Colleen Keyes; Gad Getz; Dora Dias-Santagata; Rebecca S Heist; Jochen Lennerz; Lecia V Sequist; Cyril H Benes; A John Iafrate; Mari Mino-Kenudson; Jeffrey A Engelman; Alice T Shaw
Journal:  Cancer Discov       Date:  2016-07-18       Impact factor: 39.397

2.  Pan-Trk Immunohistochemistry Is an Efficient and Reliable Screen for the Detection of NTRK Fusions.

Authors:  Jaclyn F Hechtman; Ryma Benayed; David M Hyman; Alexander Drilon; Ahmet Zehir; Denise Frosina; Maria E Arcila; Snjezana Dogan; David S Klimstra; Marc Ladanyi; Achim A Jungbluth
Journal:  Am J Surg Pathol       Date:  2017-11       Impact factor: 6.394

3.  First-line crizotinib in ALK-positive lung cancer.

Authors:  Benjamin J Solomon; Tony Mok
Journal:  N Engl J Med       Date:  2015-02-19       Impact factor: 91.245

4.  EML4-ALK fusion variant V3 is a high-risk feature conferring accelerated metastatic spread, early treatment failure and worse overall survival in ALK+ non-small cell lung cancer.

Authors:  Petros Christopoulos; Volker Endris; Farastuk Bozorgmehr; Mei Elsayed; Martina Kirchner; Jonas Ristau; Ivo Buchhalter; Roland Penzel; Felix J Herth; Claus P Heussel; Martin Eichhorn; Thomas Muley; Michael Meister; Jürgen R Fischer; Stefan Rieken; Arne Warth; Helge Bischoff; Peter Schirmacher; Albrecht Stenzinger; Michael Thomas
Journal:  Int J Cancer       Date:  2018-01-24       Impact factor: 7.396

5.  Prospective Comprehensive Molecular Characterization of Lung Adenocarcinomas for Efficient Patient Matching to Approved and Emerging Therapies.

Authors:  Emmet J Jordan; Hyunjae R Kim; Maria E Arcila; David Barron; Debyani Chakravarty; JianJiong Gao; Matthew T Chang; Andy Ni; Ritika Kundra; Philip Jonsson; Gowtham Jayakumaran; Sizhi Paul Gao; Hannah C Johnsen; Aphrothiti J Hanrahan; Ahmet Zehir; Natasha Rekhtman; Michelle S Ginsberg; Bob T Li; Helena A Yu; Paul K Paik; Alexander Drilon; Matthew D Hellmann; Dalicia N Reales; Ryma Benayed; Valerie W Rusch; Mark G Kris; Jamie E Chaft; José Baselga; Barry S Taylor; Nikolaus Schultz; Charles M Rudin; David M Hyman; Michael F Berger; David B Solit; Marc Ladanyi; Gregory J Riely
Journal:  Cancer Discov       Date:  2017-03-23       Impact factor: 39.397

6.  Patient-reported outcomes and quality of life in PROFILE 1007: a randomized trial of crizotinib compared with chemotherapy in previously treated patients with ALK-positive advanced non-small-cell lung cancer.

Authors:  Fiona Blackhall; Dong-Wan Kim; Benjamin Besse; Hiroshi Nokihara; Ji-Youn Han; Keith D Wilner; Arlene Reisman; Shrividya Iyer; Vera Hirsh; Alice T Shaw
Journal:  J Thorac Oncol       Date:  2014-11       Impact factor: 15.609

7.  Differential protein stability and ALK inhibitor sensitivity of EML4-ALK fusion variants.

Authors:  Johannes M Heuckmann; Hyatt Balke-Want; Florian Malchers; Martin Peifer; Martin L Sos; Mirjam Koker; Lydia Meder; Christine M Lovly; Lukas C Heukamp; William Pao; Ralf Küppers; Roman K Thomas
Journal:  Clin Cancer Res       Date:  2012-08-21       Impact factor: 12.531

Review 8.  ALK in lung cancer: past, present, and future.

Authors:  Alice T Shaw; Jeffrey A Engelman
Journal:  J Clin Oncol       Date:  2013-02-11       Impact factor: 44.544

9.  Microtubule association of EML proteins and the EML4-ALK variant 3 oncoprotein require an N-terminal trimerization domain.

Authors:  Mark W Richards; Laura O'Regan; Daniel Roth; Jessica M Montgomery; Anne Straube; Andrew M Fry; Richard Bayliss
Journal:  Biochem J       Date:  2015-05-01       Impact factor: 3.857

Review 10.  Molecular mechanisms that underpin EML4-ALK driven cancers and their response to targeted drugs.

Authors:  Richard Bayliss; Jene Choi; Dean A Fennell; Andrew M Fry; Mark W Richards
Journal:  Cell Mol Life Sci       Date:  2016-01-11       Impact factor: 9.261
View more
  1 in total

Review 1.  Targeting phosphatidylserine for Cancer therapy: prospects and challenges.

Authors:  Wenguang Chang; Hongge Fa; Dandan Xiao; Jianxun Wang
Journal:  Theranostics       Date:  2020-07-23       Impact factor: 11.556
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.